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There is a growing appreciation of the important role of resolution mediators in the successful
termination of the inflammatory response. Here, we discuss the potential importance of the lipid and
peptide proresolving mediators, in particular the resolvins and chemerin-derived peptides, which
mediate their effects through specific G protein-coupled receptors (GPCRs).Introduction
The typical result of inflammation is removal of harmful stimuli,
such as pathogens, followed by resolution; that is, the restoration
of affected tissues to their normal structural and functional state.
Until recently, it was thought that resolution of the acute inflam-
matory response was a passive process; it is now evident that
endogenous anti-inflammatory and proresolving pathways exist
to control the generation of an appropriate inflammatory response
and its resolution [1]. The obvious implication of this is that
chronic inflammatory pathologies could be in part explained by
a ‘failure to resolve’ and, hence, be a consequence, again at least
partly, to the absence or malfunction of one or more proresolving
pathways. Improved understanding of endogenous anti-inflam-
matory systems, in part through identification of novel resolution
mediators and receptors, could establish novel paradigms that not
only explain the pathology (e.g. inadequate activation of prore-
solving mechanisms and pathways), but also underpin the devel-
opment of novel drugs that can promote inflammatory resolution,
perhaps in concert with the endogenous pathways of the body [2].
A diverse array of factors has a role in inflammatory resolution,
including gaseous mediators (H2S [3]); a purine (adenosine [4]);
acetylcholine release from the vagal nerve [5]; a protease inhibitor
[secretory leukocyte protease inhibitor (SLPI) [6]]; lipids {lipoxins
[7], resolvins [8], protectins [9], maresins [10], and cyclopentenone§ This is an open-access article distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use, distribution
and reproduction in any medium, provided the original author and source
are credited.
Corresponding author:. Perretti, M. (m.perretti@qmul.ac.uk)
1 Present address: School of Physiology and Pharmacology, Medical Sciences,
Bristol University, Bristol, United Kingdom.
1186 www.drugdiscoverytoday.com 1359-6446/06/$ - see front matter  2014 The Authorprostaglandins [15-deoxy-delta-12,14-prostaglandin J2 (15d-
PGJ2)] [2]}; proteins (annexin A1 [11]); and peptides (annexin,
melanocortin and chemerin-derived peptides [12–16]) (Tables 1
and 2). In this noncomprehensive review, we focus on a subset of
membrane anti-inflammatory GPCRs as effectors of resolution,
ChemR23 (CMKLR1), GPR32 and FPR2/ALX, which transduce the
proresolving signals of chemerin peptides, resolvin E1 (RvE1) and
resolvin D1 (RvD1) (Fig. 1).
Proresolving lipid agonists: resolvins
We first focus on the role that resolvins, as examples of proresol-
ving lipids, have in inflammatory resolution. Omega-3 polyunsat-
urated fatty acids (PUFA) are known to be beneficial for health.
Indeed, population studies suggest that these lipids have a pre-
ventative effect in rheumatoid arthritis (RA), with lower preva-
lence observed in the Japanese and Inuit population, who
consume large amounts of oily fish rich in omega-3 PUFA. In
corroboration, clinical studies have revealed that dietary supple-
mentation with omega-3 PUFA is efficacious in reducing joint
pain, morning stiffness, and nonsteroidal anti-inflammatory drugs
(NSAID) usage in patients with RA [17]. Additionally, consump-
tion of omega-3 PUFA has favorable effects for cardiovascular
health [18], which can become compromised in patients with
RA. However, the mechanisms by which omega-3 PUFAs exert
their beneficial effects has not yet been fully explored.
Recently, a new genus of autacoids was identified in resolving
exudates that exert potent, protective properties and control the
duration and magnitude of an inflammatory response. These
include the lipoxins from arachidonic acid and the omega-3-
derived resolvins, protectins, and maresins [19]. Here, we focus
on two of the resolvins (resolution-phase interaction products)s. Published by Elsevier Ltd. All rights reserved. http://dx.doi.org/10.1016/j.drudis.2014.06.023
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TABLE 1
A selection of proresolving mediators and their receptors
Resolution mediator (abbreviation) Synonyms Class Receptor(s) Refs
Annexin A1 (AnxA1) Lipocortin A1 FPR2/ALX [11,12,55]
Galectin 1 (Gal1) Galaptin, LGALS1 Protein CD7, CD43, CD45, integrins, CD2, CD3 [56–58]
Galectin 9 (Gal9) LGALS9 TIM-3 [56,59]
Ac2-26 FPR1, FPR2/ALX [30,60]
Alpha-melanocortin-stimulating hormone (aMSH) a-Melanotropin Peptide MC3R [61,62]
Chemerin15 (C15) ChemR23/CMKLR1 [16,49]
Lipoxin A4 (LXA4) FPR2/ALX, GPR32 [7,28,63]
Resolvin D1 (RvD1) FPR2/ALX, GPR32 [28,64]
Resolvin D2 (RvD2) ? [20,26]
Resolvin E1 (RvE1) Lipid ChemR23, BLT1 [52,65,66]
Maresins ? [10]
Protectin D1 ? [9,67]
15-Deoxy-prostaglandin J2 (15d-PGJ2) Cyclopentenone prostaglandin PPARg [68]
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enzymatically biosynthesized from omega-3 eicosapentaenoic
acid and docosahexaenoic acid, respectively.
Resolvins exert potent anti-inflammatory and proresolving
actions not only in acute inflammatory models, but also in models
of chronic disease, including diabetes, sepsis, retinopathy, asthma,
atherosclerosis, and periodontitis. RvD1, D2, and E1 also exhibit
anti-infective actions, enhancing the containment, killing, and
clearance of bacteria to promote catabasis [20–22]. Furthermore,
resolvins help maintain vascular homeostasis; RvE1 counter-reg-
ulates platelet activation [23] and decreases platelet-derived
growth factor-stimulated vascular smooth muscle cell activation
[24]. Additionally, RvD2 stimulates vasoprotective prostacyclin
and nitric oxide release from vascular endothelial cells [20]. Resol-
vins were recently identified as potent analgesics; 17R-RvD1TABLE 2
Ligands for selected resolution receptors
Receptor Ligands Refs
BLT1 LTB4 [69]
RvE1 [52]
ChemR23 Chemerin (TIG2, RARRES2) [16,38]
C15a [16,49]
RvE1 [52,66]
FPR1 fMLF [70]
Mitochondrial formyl peptides [71]
Ac2-26 [13,72]
FPR2 AnxA1 [73]
CCL23 [74]
Humanin [75,76]
SHAAGtide [77]
Ac2-26 [13,72]
SAA [78]
uPAR [79]
PrP (Prion protein) [80]
LL-37 (Cathelicidin) [81]
Temporin [82]
Lipoxin A4 [83]
WKYMVm [84,85]
a Receptor specificity shown indirectly through use of receptor-knockout cells and mice.(100 ng intraperitoneally twice daily) is antihyperalgesic, reducing
hind paw withdrawal frequency in a model of adjuvant-induced
arthritis, which was associated with decreased tumor necrosis
factor (TNF)-a and interleukin (IL)-1b levels within the paw
[25]. Most recently, RvD1, D2, and E1 were documented as endog-
enous inhibitors for transient receptor potential vanilloid 1
(TRPV1) and TRP ankyryn 1 (TRPA1) currents; these receptors
contribute to inflammatory pain via peripheral and central sensi-
tization, thus explaining the analgesic actions of resolvins [26].
The bioactions of resolvins are mediated via specific GPCRs
(Fig. 1). RvE1 acts as an agonist at two GPCRs, namely ChemR23
and as a partial agonist on the leukotriene B4 (LTB4) receptor
(BLT1), thus competing with LTB4 for binding (reviewed in
[27]). RvD1 is also known to act via two GPCRs, which were
identified and validated using a GPCR/beta-arrestin coupled
system, the lipoxin A4 (LXA4) and annexin-A1 receptor [formyl
peptide-like 2 (FPR2)/ALX] and an orphan receptor GPR32 on
human leukocytes [28] (Fig. 1). Specific binding experiments
revealed that RvD1 binds with high affinity (Kd = 0.2 nM) to
human neutrophils. RvD1 binding could be partially displaced
(approximately 60%) by LXA4, whereas no competition was
observed with the annexin peptide Ac2-12, conferring indepen-
dent peptide and/or lipid binding sites. Receptors for other
resolvins are yet to be determined, but are likely to be high-affinity
GPCRs based on their potency, stereoselective actions and becau-
setheir actions can be blocked with the selective Gai-coupled
GPCR inhibitor, pertussis toxin [20,26].
Transgenic mice overexpressing human FPR2/ALX exhibited
reduced neutrophil infiltration in zymosan peritonitis [29] and
mice lacking the murine homologue receptor displayed an exac-
erbated response to arthritogenic serum [30], further supporting a
protective role for this receptor in inflammation. Indeed, increased
levels of the proresolving mediator LXA4 and FPR2/ALX are
detected in human pathologies, including RA [31] and acute
post-streptococcal glomerulonephritis [32], suggesting that pro-
tective mediators and their receptors are may be operative within
inflammatory settings to aid resolution. Therefore, endogenous
lipid mediators are temporally and spatially biosynthesized towww.drugdiscoverytoday.com 1187
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FIGURE 1
Key cellular actions of resolvins and the chemerin peptide C15. Resolvins act in a stereospecific manner on multiple cell types via specific G protein-coupled
receptors (GPCRs) to limit neutrophil (PMN) activation and recruitment and to stimulate nonphlogistic macrophage phagocytosis. Both RvD1 and RvE1 act at two
GPCRs, RvD1 signals via ALX/FPR2 and an orphan receptor GPR32 on human leukocytes, whereas RvE1 acts as an agonist at ChemR23 and as a partial agonist on
the LTB4 receptor (BLT1), thus competing with LTB4 for binding (reviewed in [27]). The chemerin peptide C15 is also known to signal via ChemR23 to reduce PMN
and monocyte recruitment and limit macrophage activation. Abbreviations: ALX/FPR2, lipoxin A4 receptor/annexin-A1 receptor/formyl peptide-like 2; LTB4,
leukotriene B4; RvD1, resolvin D1; RvE1, resolvin E1;.
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which initiates anti-inflammatory and proresolving signals to
terminate inflammation. However, when these endogenous
counter-regulatory circuits fail, inflammation perpetuates, as ob-
served in pathologies such as atherosclerosis [33] and periodontitis
[34], which are associated with chronic low-grade inflammation.
Proresolving peptide agonists: chemerin and its
peptides
Chemerin is a chemoattractant protein less commonly known as
retinoic acid receptor responder (RARRES2) and tazarotene-in-
duced gene-2 (TIG-2). Chemerin is found in the circulation and
in inflammatory exudates including ascitic and synovial fluid
[35,36]. Secreted as an inactive precursor, pro-chemerin undergoes
C-terminal proteolytic cleavage by serine proteases to generate the
active chemoattractant protein. These enzymes include those of
the coagulation (factor VII) and fibrinolytic (plasmin) cascades,
and those derived post-neutrophil degranulation (elastase and
cathepsin G) [35–37]. Chemerin acts as a plasmacytoid dendritic
cell, natural killer cell, and macrophage chemoattractant [38–40].
The chemotactic effects of chemerin are mediated through the
GPCR ChemR23, although chemerin can also bind to GPR1 and1188 www.drugdiscoverytoday.comchemokine (C–C motif) receptor-like 2 (CCRL2) [chemokine re-
ceptor on activated macrophages (CRAM)] [41,42]. The binding
sites of chemerin on each of its receptors have yet to be described
and it is currently unknown where, or indeed if, chemerin peptides
bind to the aforementioned chemerin receptors, although the
chemerin-derived peptide C15 clearly mediates its effects through
ChemR23. With the exception of the ability of chemerin to induce
a calcium flux response in GPR1-transfected cells, its functional
relevance as a GPR1 ligand in vitro or in vivo is unknown [43]. The
situation with respect to CCRL2 is a little clearer. CCRL2, similar to
the Duffy antigen for chemokine receptor (DARC) and D6, is not
thought to be a signaling receptor. Indeed, CCRL2 binds but does
not internalize chemerin, thus increasing local chemerin concen-
trations available to interact with ChemR23 [44]. CCRL2/ mice
display reduced tissue swelling, suggesting a role for the receptor in
edema; however, CCRL2 has several identified ligands, including
chemokine (C–C motif) ligand 5 and 19 (CCL5 and CCL19); thus,
it is unclear whether the phenotype described is the result of
changes in chemerin sequestration [45].
Chemerin was initially described as a transcript upregulated by
the anti-inflammatory psoriasis drug, tazarotene, in skin raft cul-
tures [46] and induced by the anti-inflammatory compounds 1,25
Drug Discovery Today  Volume 19, Number 8 August 2014 REVIEWSdihydroxyvitamin D3 and dexamethasone [47] in an osteoblast
cell line, suggesting that it has beneficial roles in inflammation.
Indeed, chemerin can undergo further proteolysis of the C termi-
nus by cysteine proteases, primarily macrophage-derived cathe-
psins, to generate peptides endowed with either anti-
inflammatory or antimicrobial properties [16,48]. The 15-aminoVCAM-1 E-Sele
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FIGURE 2
Pathways and effects for chemerin, chemerin peptides and ChemR23 in inflamm
neutrophil degranulation at the inflammatory site, generating the potent chemoat
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and function.acid chemerin-derived peptide C15 (AGEDPHGYFLPGQFA) (Figs 1
and 2) inhibits macrophage activation in picomolar concentra-
tions and, in the context of the acute inflammatory response, C15
suppresses neutrophil and monocyte recruitment (up to 65%) and
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ation. (i) Pro-chemerin is cleaved by proteolytic enzymes released upon
tractant chemerin [35,36,38]. (ii) Chemerin engages ChemR23 on circulating
 [38]. (iii) Activated MKs release proteolytic enzymes to eliminate and digest
tent anti-inflammatory peptides, capable of engaging ChemR23 to reprogram
g phenotype. (v) The expression of proinflammatory mediators by MKs is
 (IL)-10 and tumor growth factor (TGF)-b are induced. Chemerin peptides (e.g.
 at the inflammatory site, thereby aiding restoration of normal tissue structure
www.drugdiscoverytoday.com 1189
R
ev
ie
w
s
 P
O
S
T
S
C
R
E
E
N
REVIEWS Drug Discovery Today  Volume 19, Number 8 August 2014
R
eview
s
P
O
S
T
S
C
R
E
E
NImportantly, C15 promotes the nonphlogistic clearance of apo-
ptotic neutrophils and microbial particles from the inflammatory
milieu, thus contributing to the resolution of inflammation [49]
(see Fig. 2 for a dynamic scheme of the chemerin–C15–ChemR23
axis). Chemerin can also be cleaved by cathepsin L and K to
generate antimicrobial peptides capable of reducing growth of a
spectrum of bacteria, including Escherichia coli, Klebsiella pneumo-
nia [48]. Furthermore, chemerin administration in a lipopolysac-
charide (LPS)-induced lung inflammation model resulted in
dampened neutrophil recruitment and inflammatory cytokine
expression indicative of in vivo proteolysis to afford generation
of the anti-inflammatory and proresolving species [50]. Collective-
ly, these data describe a unique protein requiring proteolytic
processing to activate its latent chemoattractant properties and
further proteolysis to release separate antimicrobial and anti-in-
flammatory and/or proresolving peptides.
The anti-inflammatory and proresolving effects of C15 are
mediated by ChemR23 because ChemR23/ cells and mice are
unresponsive to the peptide, whereas neutralization of endoge-
nous chemerin species results in exacerbation of peritonitis
[16,49]. Furthermore, LPS-induced lung inflammation is also ex-
acerbated in ChemR23/ mice [50], whereas in a model of viral
pneumonia, ChemR23/ animals exhibited higher mortality,
delayed viral clearance, and increased neutrophil recruitment
[51]. Collectively, these studies demonstrate an important anti-
inflammatory and proresolving role for chemerin peptides and
ChemR23 in acute inflammation.
Binding of chemerin and RvE1 to ChemR23 has been demon-
strated using radiolabelled agonists; however, conclusive binding
studies have yet to be performed for C15 [38,52]. One group has,
surprisingly, not reproduced any of the data obtained with RvE1 or
C15. In particular, Luangsay et al. failed to show displacement of
chemerin from its binding site on ChemR23 by RvE1 or C15 and
concluded that they are not ligands for ChemR23 [50]. It is
established for other GPCRs, such as formyl peptide like 2
(FPR2), that the proinflammatory serum amyloid A (SAA) binds
to a distinct site on the receptor to the anti-inflammatory protein
AnxA1 [13,53]; thus, one cannot conclude that lack of chemerin
displacement by RvE1 and/or C15 means that these mediators are
not ligands for the receptor. Indeed, the complexity is emerging
and it is now accepted that these receptors rarely function as one
ligand–one signal receptors. Given that the binding sites for C15,
RvE1, and chemerin within ChemR23 have yet to be mapped, we
propose three potential scenarios to explain the apparent discre-
pancies: (i) the anti-inflammatory molecules C15 and RvE1 bind to1190 www.drugdiscoverytoday.coma distinct, and as yet, unidentified site on ChemR23 to the che-
moattractant chemerin to exert their opposing effects on inflam-
mation; (ii) RvE1 and/or C15 displace chemerin from ChemR23
but interact with different GPCR residues, triggering different
signaling pathways; or (iii) ligand-biased heterodimerization of
ChemR23 with another, possibly related, GPCR could allow bind-
ing of chemerin peptides and RvE1 to a receptor that is dimerized
with ChemR23 but still produces ChemR23 downstream effects.
This scenario has been demonstrated for FPR2/ALX, which can
heterodimerize with Leukotriene B4 receptor (BLT1) [54] and can
also convey both pro-inflammatory signals and have lipid, pro-
tein, and peptide ligands. With continued research, we predict
that more examples of peptido- and lipid-based agonists sharing
the same receptor will be unveiled and perhaps could become a
paradigm for GPCRs.
Concluding remarks
The discovery that specific GPCRs can transduce signals from both
lipids and peptides is not only a novel aspect in receptor biology
that is likely to become more common in the years ahead, but is
also endowed with important opportunities for drug discovery.
We postulate that nature has economized to make use of the same
receptor to convey proresolving, inhibitory, and buffering signals
by short-lived lipids and also by peptides and/or proteins, with
longer half-lives (hours versus minutes), and often generated at
later stages of inflammation. One example that emerges from this
approach to research is that of ChemR23, a specific GPCR that
signals effects of RvE1 and C15. We conclude that a better under-
standing of the pharmacology of these receptors, especially in
chronic inflammatory settings, could guide innovative drug dis-
covery programs aimed at capitalizing the fundamental actions of
these effectors of resolution. This has already begun to happen,
with a stable isopropyl ester analog of RvE1, RX-10045 (Resolvyx
Pharmaceuticals) proving efficacious in a Phase II clinical trial to
treat the signs and symptoms of dry eye (Clinicaltrials.gov identi-
fier: NCT00799552), and with C15 being an ideal candidate for
canonical structure–activity relation studies to develop novel anti-
inflammatory therapeutics.
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